160 related articles for article (PubMed ID: 33856599)
1. A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma.
Chan SL; Cheng PNM; Liu AM; Chan LL; Li L; Chu CM; Chong CCN; Lau YM; Yeo W; Ng KKC; Yu SCH; Mok TSK; Chan AWH
Invest New Drugs; 2021 Oct; 39(5):1375-1382. PubMed ID: 33856599
[TBL] [Abstract][Full Text] [Related]
2. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
Cheng PN; Lam TL; Lam WM; Tsui SM; Cheng AW; Lo WH; Leung YC
Cancer Res; 2007 Jan; 67(1):309-17. PubMed ID: 17210712
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.
Lam TL; Wong GK; Chong HC; Cheng PN; Choi SC; Chow TL; Kwok SY; Poon RT; Wheatley DN; Lo WH; Leung YC
Cancer Lett; 2009 May; 277(1):91-100. PubMed ID: 19138817
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients.
Yau T; Cheng PNM; Chiu J; Kwok GGW; Leung R; Liu AM; Cheung TT; Ng CT
Invest New Drugs; 2022 Apr; 40(2):314-321. PubMed ID: 34735674
[TBL] [Abstract][Full Text] [Related]
5. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
Thongkum A; Wu C; Li YY; Wangpaichitr M; Navasumrit P; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Ruchirawat M; Savaraj N
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587170
[TBL] [Abstract][Full Text] [Related]
6. Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors.
Cheng PNM; Liu AM; Bessudo A; Mussai F
Invest New Drugs; 2021 Dec; 39(6):1633-1640. PubMed ID: 34287772
[TBL] [Abstract][Full Text] [Related]
7. Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma.
Yau T; Cheng PN; Chan P; Chen L; Yuen J; Pang R; Fan ST; Wheatley DN; Poon RT
Invest New Drugs; 2015 Apr; 33(2):496-504. PubMed ID: 25666409
[TBL] [Abstract][Full Text] [Related]
8. Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma.
De Santo C; Cheng P; Beggs A; Egan S; Bessudo A; Mussai F
J Hematol Oncol; 2018 May; 11(1):68. PubMed ID: 29776373
[TBL] [Abstract][Full Text] [Related]
9. Bioengineered arginase I increases caspase-3 expression of hepatocellular and pancreatic carcinoma cells despite induction of argininosuccinate synthetase-1.
Glazer ES; Kaluarachchi WD; Massey KL; Zhu C; Curley SA
Surgery; 2010 Aug; 148(2):310-8. PubMed ID: 20466402
[TBL] [Abstract][Full Text] [Related]
10. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
Feun LG; Marini A; Walker G; Elgart G; Moffat F; Rodgers SE; Wu CJ; You M; Wangpaichitr M; Kuo MT; Sisson W; Jungbluth AA; Bomalaski J; Savaraj N
Br J Cancer; 2012 Apr; 106(9):1481-5. PubMed ID: 22472884
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
Harding JJ; Do RK; Dika IE; Hollywood E; Uhlitskykh K; Valentino E; Wan P; Hamilton C; Feng X; Johnston A; Bomalaski J; Li CF; O'Reilly EM; Abou-Alfa GK
Cancer Chemother Pharmacol; 2018 Sep; 82(3):429-440. PubMed ID: 29971467
[TBL] [Abstract][Full Text] [Related]
12. The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-100.
De Santo C; Booth S; Vardon A; Cousins A; Tubb V; Perry T; Noyvert B; Beggs A; Ng M; Halsey C; Kearns P; Cheng P; Mussai F
Int J Cancer; 2018 Apr; 142(7):1490-1502. PubMed ID: 29168171
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma.
Yau T; Cheng PN; Chan P; Chan W; Chen L; Yuen J; Pang R; Fan ST; Poon RT
Invest New Drugs; 2013 Feb; 31(1):99-107. PubMed ID: 22426640
[TBL] [Abstract][Full Text] [Related]
14. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Manca A; Sini MC; Izzo F; Ascierto PA; Tatangelo F; Botti G; Gentilcore G; Capone M; Mozzillo N; Rozzo C; Cossu A; Tanda F; Palmieri G
Oncol Rep; 2011 Jun; 25(6):1495-502. PubMed ID: 21424129
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
16. Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma.
Wu L; Li L; Meng S; Qi R; Mao Z; Lin M
J Gastroenterol Hepatol; 2013 Feb; 28(2):365-8. PubMed ID: 23339388
[TBL] [Abstract][Full Text] [Related]
17. Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients.
Yang H; Lin M; Xiong F; Yang Y; Nie X; McNutt MA; Zhou R
Surg Today; 2011 Jun; 41(6):810-7. PubMed ID: 21626328
[TBL] [Abstract][Full Text] [Related]
18. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.
Yang TS; Lu SN; Chao Y; Sheen IS; Lin CC; Wang TE; Chen SC; Wang JH; Liao LY; Thomson JA; Wang-Peng J; Chen PJ; Chen LT
Br J Cancer; 2010 Sep; 103(7):954-60. PubMed ID: 20808309
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.
El Dika I; Capanu M; Chou JF; Harding JJ; Ly M; Hrabovsky AD; Do RKG; Shia J; Millang B; Ma J; O'Reilly EM; Abou-Alfa GK
Cancer Med; 2020 Oct; 9(20):7453-7459. PubMed ID: 32841541
[TBL] [Abstract][Full Text] [Related]
20. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Qin S; Ryoo BY; Lu SN; Yen CJ; Feng YH; Lim HY; Izzo F; Colombo M; Sarker D; Bolondi L; Vaccaro G; Harris WP; Chen Z; Hubner RA; Meyer T; Sun W; Harding JJ; Hollywood EM; Ma J; Wan PJ; Ly M; Bomalaski J; Johnston A; Lin CC; Chao Y; Chen LT
Ann Oncol; 2018 Jun; 29(6):1402-1408. PubMed ID: 29659672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
